Document is current
Any future updates will be listed below
-
Authors
Wurm, Sonja https://orcid.org/0000-0002-7540-737X
Moritz, Jennifer M. https://orcid.org/0000-0001-5574-6692
Petzer, Verena https://orcid.org/0000-0002-9205-1440
Wolf, Dominik https://orcid.org/0000-0002-4761-075X
Gleixner, Karoline V. https://orcid.org/0000-0001-5753-0203
Sperr, Wolfgang R. https://orcid.org/0000-0003-3288-8027
Groiss, Christina https://orcid.org/0009-0008-9096-0502
Machherndl-Spandl, Sigrid https://orcid.org/0009-0007-1247-7948
Eisenwort, Gregor https://orcid.org/0000-0003-2735-4645
Koller, Elisabeth https://orcid.org/0000-0002-9912-0461
Schoeche, Johannes https://orcid.org/0000-0002-4740-5166
Petrasch, Clemens https://orcid.org/0000-0001-5009-5579
Singer, Josef https://orcid.org/0000-0002-8701-2412
Mayer, Daniel M.
Pregartner, Gudrun https://orcid.org/0000-0002-9899-0502
Heine, Annkristin https://orcid.org/0000-0002-5298-9880
Wölfler, Albert https://orcid.org/0000-0002-3112-9857
Sill, Heinz https://orcid.org/0000-0003-0993-4371
Reinisch, Andreas https://orcid.org/0000-0001-9333-7689
Zebisch, Armin https://orcid.org/0000-0002-4861-7021
-
Funding
Funding for this research was provided by:
Austrian Science Fund (Grant-DOI 10.55776/P36672, Grant-DOI 10.55776/PAT1753824)
Leukämiehilfe Steiermark
- License Information
-
More Information
Article History
Received: 17 June 2025
Revised: 19 September 2025
Accepted: 13 October 2025
First Online: 22 October 2025
Competing interests
: SW: Honoraria: AbbVie, Beigene, CSL Behring; JMM: honoraria: AbbVie, AOP Health; VP: honoraria: BMS, GSK, Novartis, Johnson & Johnson, AOP-Health, Takeda; research funding: BMS; travel support/conference attendance: J&J, Pfizer, Gilead, GSK, AOP-Health; DW: none; KVG: honoraria: Jazz pharmaceuticals, AbbVie, Novartis, Servier, Blueprint Medicines, Incyte, Celgene Corporation, Astellas, Daiichi Sankyo; WRS: Scientific grants, honoraria, or travel support: AbbVie, Astellas, Blueprint, BMS-Celgene, Daichi-Sankyo, Deciphera, Jazz, Laboratoires Delbert, Novartis, Otsuka, Pfizer, Servier, StemLine, Thermo Fishernone; CG: none; SMS: honoraria: Abbvie, Alexion, Amgen, BMS/Celgene, Daiichi-Sankyo, Janssen, Jazz, Novartis, Pfizer, Servier; GE: honoraria: Abbvie, Servier, Jazz Pharmaceuticals, SOBI; EK: honoraria and advisory boards: Abbvie, Astellas, Beigene, Daichi Sankyo, Jazz, Servier; JS: honoraria and advisory boards: Amgen, AOP, Beigene, BMS, GSK, Johnson & Johnson, Miltenyi Biomedicine, Servier; travel grants: Johnson & Johnson, Roche; CP: honoraria and advisory boards: AbbVie, Beigene, MSD, Johnson & Johnson, Jazz Pharmaceuticals, Servier; travel grants: Johnson & Johnson, Sanofi, Beigene, MSD; JSi: honoraria and consultancy: AbbVie, Amgen, Angelini Pharma, Gilead, Janssen, Kite, Merck, Merck Sharp & Dohme, Miltenyi, Novartis, Pfizer, Roche, and Servier; DMM: honoraria and advisory boards: Roche, Amgen, Janssen, Eli Lilly, BeiGene, AbbVie; GP: none; AH: honoraria, consultancy or travel support: Incyte, Servier, Roche, Sanofi, BMS/Celgene, J&J, Amgen, BeOne, Novartis, Miltenyi, Takeda, Sobi, Abbvie, Novartis, Lilly, Pfizer; AW: honoraria: AbbVie, BMS/Celgene, Daiichi Sankyo, Jazz, Novartis; research funding: BMS/Celgene; HS: none; AR: honoraria: AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Jazz, Servier, Sobi, CSL-Behring, Pfizer, Novartis, Biomarin; consulting or advisory role: AbbVie, Bristol Myers Squibb, Servier; Sobi, Novartis, Biomarin; Research Funding: Celgene/BMS, Gilead; Travel accommodation: Servier, BMS, Abbvie, Beigene, Sobi, Novartis, Roche, AOP; AZ: honoraria: Astellas, AbbVie, Bristol Myers Squibb, Daiichi Sankyo, JAZZ, Novartis, Otsuka, Servier; consulting or advisory role: Astellas, AbbVie, Bristol Myers Squibb, Delbert Pharma, JAZZ, Novartis, Servier; Research Funding: Apollo Therapeutics; Travel accommodation: Astra Zeneca.
